Luca Licata, Medical Oncologist at San Raffaele Hospital, shared an article that He and his collogues co-authored on X:
“Another step forward for precision immunotherapy in breast cancer!
Just out in NPJ Journals Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in TNBC.”
Title: Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple – negative breast cancer.
Authors: Justin M. Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, Antonio Anton, Stefania Russo, Elena Sevillano, Eva Maria Ciruelos, Richard Greil, Vladimir Semiglazov, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Stefania Zambelli, Giulia Viale, Maurizio Callari, Giuseppe Viale, Lajos Pusztai, Giampaolo Bianchini
Read the full article on NPJ Journals.
Read more posts featuring Luca Licata on OncoDaily.